3151 - 3200 of 9156 Results
Title
Year
- Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study2011OPENTitle: Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker StudyJournal Name: Movement DisordersPublisher: WileyVol: 26Issue #: 12Start Page: 2283End Page: 2286Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.23934Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3337217Citation Count: 25
-
OPENTitle: Comparison of enrollees and decliners of Parkinson disease sham surgery trialsJournal Name: Movement DisordersPublisher: WileyVol: 27Issue #: 4Start Page: 506End Page: 511Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.24940Best OA location URL: https://hdl.handle.net/2027.42/90524Citation Count: 20
-
OPENTitle: Parkinson's disease, cortical dysfunction, and alpha‐synucleinJournal Name: Movement DisordersPublisher: WileyVol: 26Issue #: 8Start Page: 1436End Page: 1442Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.23697Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3154995Citation Count: 25
-
OPENTitle: Genetic modification of the association of paraquat and Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 27Issue #: 13Start Page: 1652End Page: 1658Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.25216Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3572192Citation Count: 94
-
RESTRICTEDTitle: Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 26Issue #: 10Start Page: 1875End Page: 1880Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.23746Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3972755Citation Count: 41
-
OPENTitle: Brain biochemistry in autopsied patients with essential tremorJournal Name: Movement DisordersPublisher: WileyVol: 27Issue #: 1Start Page: 113End Page: 117Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.24004Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3261329Citation Count: 54
-
OPENTitle: Hedonic and behavioral deficits associated with apathy in Parkinson's disease: Potential treatment implicationsJournal Name: Movement DisordersPublisher: WileyVol: 28Issue #: 9Start Page: 1301End Page: 1304Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.25496Best OA location URL: http://doi.org/10.1002/mds.25496Citation Count: 38
-
OPENTitle: Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutationsJournal Name: Movement DisordersPublisher: WileyVol: 28Issue #: 14Start Page: 1966End Page: 1971Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.25647Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3859844Citation Count: 143
-
OPENTitle: Highlights of the Stockholm Congress: A Clinician's PerspectiveJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 1Issue #: 4Start Page: 277End Page: 279Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12093Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12093Citation Count: 0
-
OPENTitle: Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's DiseaseJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 19Issue #: 6Start Page: 1048End Page: 1057Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/mt.2011.11Best OA location URL: http://www.cell.com/article/S1525001616319098/pdfCitation Count: 144
-
OPENTitle: Functional Neuroprotection and Efficient Regulation of GDNF Using Destabilizing Domains in a Rodent Model of Parkinson’s DiseaseJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 2169End Page: 2180Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/mt.2013.169Best OA location URL: http://www.cell.com/article/S1525001616309431/pdfCitation Count: 61
-
OPENTitle: Neuronal gene expression correlates of Parkinson's disease with dementiaJournal Name: Movement DisordersPublisher: WileyVol: 23Issue #: 11Start Page: 1588End Page: 1595Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.22184Best OA location URL: http://doi.org/10.1002/mds.22184Citation Count: 51
-
OPENTitle: Intranigral Lentiviral Delivery of Dominant-negative TNF Attenuates Neurodegeneration and Behavioral Deficits in Hemiparkinsonian ratsJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 16Issue #: 9Start Page: 1572End Page: 1579Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/mt.2008.146Best OA location URL: http://www.cell.com/article/S1525001616320548/pdfCitation Count: 117
-
OPENTitle: Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBVJournal Name: Molecular PsychiatryPublisher: Springer Science and Business Media LLCVol: 24Issue #: 3Start Page: 322End Page: 327Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41380-018-0130-5Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/6363916Citation Count: 73
-
OPENTitle: Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 12Issue #: 10Start Page: 978End Page: 988Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(13)70210-2Best OA location URL: http://doi.org/10.1016/S1474-4422(13)70210-2Citation Count: 269
- Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease2010RESTRICTEDTitle: Impact of belief in neuroprotection on therapeutic intervention in Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 8Start Page: 1082End Page: 1086Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.22997Citation Count: 1
-
OPENTitle: Incidental Lewy body disease: Clinical comparison to a control cohortJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 5Start Page: 642End Page: 646Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.22971Best OA location URL: http://doi.org/10.1002/mds.22971Citation Count: 141
-
OPENTitle: Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy PathologyJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 2Issue #: 1Start Page: 33End Page: 38Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12104Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12104Citation Count: 5
- The relationship between uric acid levels and Huntington's disease progression2010RESTRICTEDTitle: The relationship between uric acid levels and Huntington's disease progressionJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 2Start Page: 224End Page: 228Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.22907Citation Count: 91
-
OPENTitle: LRRK2 G2019S mutations may be increased in Puerto RicansJournal Name: Movement DisordersPublisher: WileyVol: 26Issue #: 9Start Page: 1771End Page: 1773Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.23632Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3140626Citation Count: 8
-
RESTRICTEDTitle: Obesity, diabetes, and risk of Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 26Issue #: 12Start Page: 2253End Page: 2259Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.23855Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3627531Citation Count: 163
-
OPENTitle: Using global statistical tests in long‐term Parkinson's disease clinical trialsJournal Name: Movement DisordersPublisher: WileyVol: 24Issue #: 12Start Page: 1732End Page: 1739Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.22645Best OA location URL: http://doi.org/10.1002/mds.22645Citation Count: 43
- Essential tremor and Parkinson's disease: Lack of a link2011RESTRICTEDTitle: Essential tremor and Parkinson's disease: Lack of a linkJournal Name: Movement DisordersPublisher: WileyVol: 26Issue #: 3Start Page: 372End Page: 377Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.23509Citation Count: 57
-
OPENTitle: Comparative Transduction Efficiency of AAV Vector Serotypes 1–6 in the Substantia Nigra and Striatum of the Primate BrainJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 18Issue #: 3Start Page: 588End Page: 593Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/mt.2009.286Best OA location URL: http://www.cell.com/article/S1525001616323085/pdfCitation Count: 130
-
OPENTitle: Subcortical Iron Accumulation Pattern May Predict Neuropsychological Outcomes After Subthalamic Nucleus Deep Brain Stimulation: A Pilot StudyJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 12Issue #: 3Start Page: 851End Page: 863Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.3233/jpd-212833Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/9181238Citation Count: 6
-
RESTRICTEDTitle: Recent advances in establishing fluid biomarkers for the diagnosis and differentiation of alpha-synucleinopathies – a mini reviewJournal Name: Clinical Autonomic ResearchPublisher: Springer Science and Business Media LLCVol: 32Issue #: 4Start Page: 23End Page: 25Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s10286-022-00882-1Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10101699/pdf/nihms-1885470.pdfCitation Count: 0
-
OPENTitle: The Effects of Deep Brain Stimulation in Patients with Multiple System AtrophyJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 12Issue #: 8Start Page: 2595End Page: 2600Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.3233/jpd-223504Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10077954/pdf/nihms-1879945.pdfCitation Count: 14
- The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy2021OPENTitle: The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System AtrophyJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 12Issue #: 1Start Page: 105End Page: 115Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-212877Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd212877?id=journal-of-parkinsons-disease%2Fjpd212877Citation Count: 19
-
OPENTitle: FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α‐synuclein expressionJournal Name: Movement DisordersPublisher: WileyVol: 24Issue #: 3Start Page: 455End Page: 459Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.22442Best OA location URL: http://doi.org/10.1002/mds.22442Citation Count: 43
-
OPENTitle: The natural history of multiple system atrophy: a prospective European cohort studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 12Issue #: 3Start Page: 264End Page: 274Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/s1474-4422(12)70327-7Best OA location URL: http://www.thelancet.com/article/S1474442212703277/pdfCitation Count: 535
-
OPENTitle: Long-term Transgene Expression in the Central Nervous System Using DNA NanoparticlesJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 17Issue #: 4Start Page: 641End Page: 650Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/mt.2009.2Best OA location URL: http://www.cell.com/article/S152500161631557X/pdfCitation Count: 80
- Frequency of Cholinergic and Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson Disease and Evidence of Interaction Effects2014RESTRICTEDTitle: Frequency of Cholinergic and Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson Disease and Evidence of Interaction EffectsJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 72Issue #: 2Start Page: 194End Page: 194Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2014.2757Citation Count: 166
-
OPENTitle: Striatal Pleiotrophin Overexpression Provides Functional and Morphological Neuroprotection in the 6-Hydroxydopamine ModelJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 544End Page: 554Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/mt.2011.216Best OA location URL: http://www.cell.com/article/S1525001616305111/pdfCitation Count: 32
-
OPENTitle: APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson DiseaseJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 71Issue #: 11Start Page: 1405End Page: 1405Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2014.1455Best OA location URL: https://jamanetwork.com/journals/jamaneurology/articlepdf/1900308/noi140049.pdfCitation Count: 210
-
OPENTitle: Real-time MR Imaging With Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 VectorsJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 18Issue #: 8Start Page: 1490End Page: 1495Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/mt.2010.114Best OA location URL: http://www.cell.com/article/S1525001616310991/pdfCitation Count: 83
- LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons2021OPENTitle: LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary NeuronsJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 11Issue #: 3Start Page: 1187End Page: 1196Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-212562Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd212562?id=journal-of-parkinsons-disease%2Fjpd212562Citation Count: 8
-
OPENTitle: Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 7Issue #: 7Start Page: 583End Page: 590Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/s1474-4422(08)70117-0Best OA location URL: http://www.thelancet.com/article/S1474442208701170/pdfCitation Count: 1565
-
OPENTitle: β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control StudyJournal Name: Clinical EpidemiologyPublisher: Informa UK LimitedVol: Volume 15Issue #:Start Page: 695End Page: 705Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.2147/clep.s405325Best OA location URL: https://www.dovepress.com/getfile.php?fileID=90360Citation Count: 8
-
OPENTitle: Mechanisms of VPS35-mediated neurodegeneration in Parkinson's diseaseJournal Name: International Review of Movement DisordersPublisher: ElsevierVol:Issue #:Start Page: 221End Page: 244Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/bs.irmvd.2021.08.005Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/9053314Citation Count: 23
-
OPENTitle: Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation AssayJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 13Issue #: 2Start Page: 255End Page: 270Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3233/jpd-213085Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd213085?id=journal-of-parkinsons-disease%2Fjpd213085Citation Count: 11
-
OPENTitle: Hsp104 antagonizes α-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson diseaseJournal Name: Journal of Clinical InvestigationPublisher: American Society for Clinical InvestigationVol: 118Issue #: 9Start Page: 3087End Page: 3097Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1172/jci35781Best OA location URL: http://www.jci.org/articles/view/35781/files/pdfCitation Count: 196
-
OPENTitle: Heterogeneity of Cholinergic Denervation in Parkinson's Disease without DementiaJournal Name: Journal of Cerebral Blood Flow & MetabolismPublisher: SAGE PublicationsVol: 32Issue #: 8Start Page: 1609End Page: 1617Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/jcbfm.2012.60Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1038/jcbfm.2012.60Citation Count: 186
- Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation2009OPENTitle: Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradationJournal Name: Journal of Clinical InvestigationPublisher: American Society for Clinical InvestigationVol: 119Issue #: 3Start Page: 650End Page: 660Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1172/jci37617Best OA location URL: http://doi.org/10.1172/JCI37617Citation Count: 389
-
OPENTitle: Can Parkinson’s disease be cured by stimulating neurogenesis?Journal Name: Journal of Clinical InvestigationPublisher: American Society for Clinical InvestigationVol: 125Issue #: 3Start Page: 978End Page: 980Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1172/jci80822Best OA location URL: http://www.jci.org/articles/view/80822/files/pdfCitation Count: 10
-
OPENTitle: A brain network response to sham surgeryJournal Name: Journal of Clinical InvestigationPublisher: American Society for Clinical InvestigationVol: 124Issue #: 8Start Page: 3285End Page: 3288Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1172/jci77193Best OA location URL: http://www.jci.org/articles/view/77193/files/pdfCitation Count: 16
-
OPENTitle: Pathogenic Mechanisms of Cytosolic and Membrane-Enriched α-Synuclein Converge on Fatty Acid HomeostasisJournal Name: The Journal of NeurosciencePublisher: Society for NeuroscienceVol: 42Issue #: 10Start Page: 2116End Page: 2130Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-saDOI - Digital Object Identifier: 10.1523/jneurosci.1881-21.2022Best OA location URL: https://www.jneurosci.org/content/jneuro/42/10/2116.full.pdfCitation Count: 26
-
OPENTitle: Use of Florbetapir-PET for Imaging β-Amyloid PathologyJournal Name: JAMAPublisher: American Medical Association (AMA)Vol: 305Issue #: 3Start Page: 275End Page: 275Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1001/jama.2010.2008Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7041965Citation Count: 1110
-
OPENTitle: Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's diseaseJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 10Start Page: 2329End Page: 2346Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2014.03.032Best OA location URL: http://doi.org/10.1016/j.neurobiolaging.2014.03.032Citation Count: 70
-
OPENTitle: Neuroimmunology of the Interleukins 13 and 4Journal Name: Brain SciencesPublisher: MDPI AGVol: 6Issue #: 2Start Page: 18End Page: 18Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/brainsci6020018Best OA location URL: https://www.mdpi.com/2076-3425/6/2/18/pdf?version=1465804812Citation Count: 126
- Serum lipid alterations in GBA-associated Parkinson's disease2017RESTRICTEDTitle: Serum lipid alterations in GBA-associated Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 44Issue #:Start Page: 58End Page: 65Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2017.08.026Citation Count: 90